<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Vancomycin: Parenteral dosing, monitoring, and adverse effects in adults
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Vancomycin: Parenteral dosing, monitoring, and adverse effects in adults
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Vancomycin: Parenteral dosing, monitoring, and adverse effects in adults
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Richard H Drew, PharmD, MS, FCCP, FIDP
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            George Sakoulas, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            David C Hooper, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Elinor L Baron, MD, DTMH
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Nov 16, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          Vancomycin
         </a>
         is a glycopeptide antibiotic administered intravenously for treatment of patients with suspected or proven invasive gram-positive infections, including methicillin-resistant
         <em>
          Staphylococcus aureus
         </em>
         (MRSA).
        </p>
        <p>
         Appropriate dosing and administration of
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         requires consideration of the pathogen and its susceptibility, type and severity of infection, patient weight, and kidney function [
         <a href="#rid1">
          1-5
         </a>
         ]. The optimal approach to vancomycin dosing and monitoring for invasive methicillin-resistant
         <em>
          S. aureus
         </em>
         (MRSA) infections is a subject of ongoing controversy and study. Challenges include how best to optimize clinical efficacy (particularly in the setting of emerging resistance) while minimizing toxicity (primarily nephrotoxicity) [
         <a href="#rid6">
          6-9
         </a>
         ].
        </p>
        <p>
         Issues related to parenteral
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         dosing and serum concentration monitoring in adult patients will be reviewed here, including guidelines on therapeutic monitoring published in 2020 by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Disease Society, and the Society of Infectious Disease Pharmacists [
         <a href="#rid1">
          1
         </a>
         ], and by the Canadian Agency for Drugs and Technologies in Health [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
         Issues related to
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         hypersensitivity are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2083.html" rel="external">
          "Vancomycin hypersensitivity"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3423212892">
         <span class="h1">
          GENERAL PHARMACOLOGY PRINCIPLES
         </span>
        </p>
        <p class="headingAnchor" id="H1544481749">
         <span class="h2">
          Tissue penetration
         </span>
         <span class="headingEndMark">
          —
         </span>
         Following intravenous administration,
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         is distributed widely to various tissues and body fluids, with a volume of distribution ranging from 0.4 to 1 L/kg [
         <a href="#rid11">
          11
         </a>
         ]. Penetration of vancomycin varies by site and concomitant disease state. For example, limited cerebrospinal fluid penetration may be enhanced by the presence of inflamed meninges. Penetration of vancomycin into soft tissue may be impaired in patients with diabetes [
         <a href="#rid12">
          12
         </a>
         ]. Vancomycin penetration into lung tissue is limited, relative to that of simultaneous serum concentration. The ratio of lung tissue to serum concentration is about 0.25 [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3393683103">
         <span class="h2">
          Drug clearance
         </span>
         <span class="headingEndMark">
          —
         </span>
         The primary route of
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         elimination is via renal excretion of unchanged drug. While the rate of elimination is directly related to creatinine clearance [
         <a href="#rid2">
          2
         </a>
         ], accurate estimates of drug clearance based on equations estimating kidney function (notably glomerular filtration rate and/or creatinine clearance) are difficult. Among the adult patients with altered vancomycin clearance are those with critical illness, burns, those receiving renal replacement therapy, and older adults [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2215775344">
         <span class="h2">
          Pharmacokinetic/pharmacodynamic target
         </span>
         <span class="headingEndMark">
          —
         </span>
         In vitro and in vivo assessments of pharmacokinetic/pharmacodynamic (PK/PD) models demonstrate that bactericidal activity (ie, a 1- to 2-log reduction in bacterial inoculum in animal models) may be achieved when the
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         area under the 24-hour time-concentration curve to minimum inhibitory concentration determined by broth microdilution (AUC/MIC
         <sub>
          BMD
         </sub>
         ) ratio approximates or exceeds 400 mg ▪ hour/L [
         <a href="#rid1">
          1,15-17
         </a>
         ]. In general, the MIC
         <sub>
          BMD
         </sub>
         tends to be 1.5- to 2-fold lower than the MIC determined by Etest (MIC
         <sub>
          Etest
         </sub>
         ). In addition, in vitro data suggest that an AUC &lt;400 mg ▪ hour/L potentiates the emergence of MRSA resistance and vancomycin-intermediate
         <em>
          S. aureus
         </em>
         strains. Issues related to achieving the efficacy target are discussed below. (See
         <a class="local">
          'Severe S. aureus infection'
         </a>
         below.)
        </p>
        <p>
         For treatment of severe, invasive infection due to
         <em>
          S. aureus
         </em>
         , the optimal PK/PD efficacy target is considered to be an AUC/MIC
         <sub>
          BMD
         </sub>
         ratio of 400 to 600 mg ▪ hour/L. This target is based on available data for isolates with an MIC
         <sub>
          BMD
         </sub>
         of 1 mcg/mL.
        </p>
        <p>
         The target range is derived largely from observational studies of patients with MRSA bacteremia. Among the limitations of such studies is that most used simple
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         clearance formulas (based on daily vancomycin dose and estimated kidney function) to determine AUC values. In general, such formulas overestimate vancomycin clearance (by 40 to 50 percent), providing imprecise estimates of the AUC [
         <a href="#rid1">
          1,18-20
         </a>
         ].
        </p>
        <p>
         Limited data suggest that higher AUC/MIC
         <sub>
          BMD
         </sub>
         targets (&gt;600 mg ▪ hour/L) may be required in patients with endocarditis due to MRSA [
         <a href="#rid21">
          21
         </a>
         ]. However, such targets are controversial because their attainment is not always associated with successful clinical outcome and their use is associated with increased risk of nephrotoxicity [
         <a href="#rid22">
          22
         </a>
         ]. (See
         <a class="local">
          'Severe S. aureus infection'
         </a>
         below.)
        </p>
        <p>
         In patients with infection due to
         <em>
          S. aureus
         </em>
         isolates with MIC
         <sub>
          BMD
         </sub>
         ≥2 mcg/mL, clinical failure of
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         has been observed [
         <a href="#rid23">
          23-26
         </a>
         ]. For such isolates, an AUC/MIC
         <sub>
          BMD
         </sub>
         of ≥400 mg ▪ hour/L is not reliably achievable with conventional dosing methods in patients with normal kidney function [
         <a href="#rid27">
          27
         </a>
         ]. In such cases alternatives to vancomycin therapy should be considered [
         <a href="#rid1">
          1
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3164.html" rel="external">
          "Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Treatment of bacteremia"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3921041844">
         <span class="h2">
          Infusion rate
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          Vancomycin
         </a>
         should be diluted to a concentration of no more than 5 mg/mL and infused at a rate of 10 to 15 mg/minute (ie, 1000 mg over ≥1 hour). For patients who develop infusion reaction (histamine-mediated flushing during or immediately following infusion of vancomycin), a slower infusion rate (including consideration for 24-hour continuous infusion) or reduction in dose is warranted. (See
         <a class="local">
          'Infusion reaction'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3529742722">
         <span class="h1">
          APPROACH TO DOSING AND MONITORING
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          Vancomycin
         </a>
         pharmacokinetic parameters vary substantially among individual patients. Therefore, individualization of the dosing regimen (independent of method) and frequent reassessment are needed to optimize drug efficacy, minimize toxicity, and minimize emergence of resistance. In all cases, the justification for continued vancomycin therapy should be reassessed frequently, and vancomycin should be discontinued if no longer indicated.
        </p>
        <p class="headingAnchor" id="H976026418">
         <span class="h2">
          Severe S. aureus infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Severe
         <em>
          S. aureus
         </em>
         infections include (but are not limited to) bacteremia, endocarditis, osteomyelitis, prosthetic joint infection, pneumonia warranting hospitalization, or infection causing critical illness  (
         <a class="graphic graphic_table graphicRef128911" href="/z/d/graphic/128911.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
         The approach to use of
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         for management of severe
         <em>
          S. aureus
         </em>
         infections is based largely from studies of methicillin-resistant
         <em>
          S. aureus
         </em>
         (MRSA) bacteremia in adults, with limited data for pneumonia and infective endocarditis. These findings are extrapolated to management of osteomyelitis and infections of the central nervous system. (See
         <a class="medical medical_review" href="/z/d/html/3164.html" rel="external">
          "Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Treatment of bacteremia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2152.html" rel="external">
          "Antimicrobial therapy of left-sided native valve endocarditis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6993.html" rel="external">
          "Treatment of hospital-acquired and ventilator-associated pneumonia in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2235734155">
         <span class="h3">
          Selecting a dosing/monitoring method
         </span>
         <span class="headingEndMark">
          —
         </span>
         Initiation of
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         therapy for severe infection requires consideration of the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Administration method (intermittent versus continuous infusion)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Use of a loading dose
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Area under the curve (AUC)-based versus trough-based goals for determination of maintenance dosing
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H927400424">
         <span class="h4">
          Intermittent versus continuous infusion
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          Vancomycin
         </a>
         may be administered via intermittent infusion (II) or continuous infusion (CI). In general, II is the most common approach. However, CI may be an advantageous alternative in certain circumstances. (See
         <a class="local">
          'Intermittent infusion'
         </a>
         below and
         <a class="local">
          'Continuous infusion'
         </a>
         below.)
        </p>
        <p>
         Potential settings for CI include patients with critical illness (particularly those on continuous renal replacement therapy), patients receiving outpatient antimicrobial therapy, and those not tolerating intermittent infusion [
         <a href="#rid1">
          1
         </a>
         ] (see
         <a class="local">
          'Continuous renal replacement'
         </a>
         below). Potential advantages of CI include rapid pharmacokinetic (PK) target attainment, less variability in steady-state concentration, ease of serum drug concentration monitoring (given less dependence on sampling time or multiple concentrations to calculate area under the 24-hour time-concentration curve [AUC
         <sub>
          24
         </sub>
         ]), and lower potential risk of nephrotoxicity [
         <a href="#rid28">
          28-34
         </a>
         ]. Disadvantages include the need for a dedicated intravenous line or compatibility with other agents administered through the same line.
        </p>
        <p>
         Data comparing intermittent with continuous
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         administration are limited. Thus far, it is not possible to draw definitive conclusions regarding comparative efficacy or safety of CI versus II, given differences in study design, control and/or accounting for confounders, and lack of adequate statistic power.
        </p>
        <p class="headingAnchor" id="H2085411544">
         <span class="h4">
          AUC-guided versus trough-guided serum concentration monitoring
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with severe
         <em>
          S. aureus
         </em>
         infection receiving
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         via II, there are two serum concentration-based methods of determining maintenance dosing: AUC
         <sub>
          24
         </sub>
         - and trough-guided dosing. The optimal approach to vancomycin serum concentration monitoring for management invasive MRSA infections is a subject of ongoing study and active debate [
         <a href="#rid6">
          6-9
         </a>
         ].
        </p>
        <p>
         Data to support use of trough-guided dosing for optimizing drug efficacy are sparse. In one systematic review including more than 2000 patients with invasive MRSA infection, no difference in all-cause mortality was observed between patients with trough concentrations of &lt;15 mcg/mL versus ≥15 mcg/mL [
         <a href="#rid35">
          35
         </a>
         ]. Similarly, another meta-analysis including more than 1600 patients with
         <em>
          S. aureus
         </em>
         bacteremia noted no correlation between trough concentrations &gt;15 mcg/mL and rates of treatment failure, persistent bacteremia, or mortality [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p>
         As discussed above,
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         activity is best predicted by the ratio of the AUC/MIC. The AUC represents the integrated quantity of cumulative drug exposure (ie, the serum drug concentration-time curve over a defined interval). The value of AUC-based dosing has been driven by its ability to identify patients at increased risk of vancomycin-induced nephrotoxicity [
         <a href="#rid20">
          20,37
         </a>
         ]. Traditionally, given the cumbersome nature of AUC estimation in a clinical context, trough-guided dosing (maintaining trough concentrations between 15 and 20 mcg/mL) has been used a surrogate marker for the AUC. (See
         <a class="local">
          'Pharmacokinetic/pharmacodynamic target'
         </a>
         above.)
        </p>
        <p>
         However, since a trough measurement represents a single exposure point at the end of the dosing interval, a wide range of concentration-time profiles may be associated with a particular trough [
         <a href="#rid6">
          6,35,36,38-41
         </a>
         ]. In addition, trough concentrations are often obtained at inappropriate times. While use of Bayesian-based AUC calculators may liberalize such timing requirements, careful attention to timing of serum drug concentration measurement relative to drug administration is required, independent of method.
        </p>
        <p>
         Use of trough-guided dosing may be associated with higher likelihood of acute kidney injury than AUC-guided dosing. Among adults with normal kidney function managed with Bayesian software to achieve AUC of ≥400, approximately 60 percent are expected to have a
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         trough concentration below the traditional minimum target of 15 mg/L, reducing the likelihood of nephrotoxicity [
         <a href="#rid41">
          41
         </a>
         ]. While AUCs of ≥400 mg ▪ hour/L are usually obtained in patients with steady-state troughs of 15 to 20 mg/L [
         <a href="#rid27">
          27,42
         </a>
         ], such troughs are rarely needed to achieve this AUC target and may exceed the upper AUC target of 600 [
         <a href="#rid43">
          43
         </a>
         ]. (See
         <a class="local">
          'Acute kidney injury'
         </a>
         below.)
        </p>
        <p>
         In a retrospective study comparing the incidence of nephrotoxicity with AUC-guided dosing versus trough monitoring among 1,280 patients on
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         , use of AUC-guided dosing was associated with a lower likelihood of acute kidney injury (AKI; odds ratio 0.52, 95% CI 0.34-0.80) [
         <a href="#rid44">
          44
         </a>
         ]. Similarly, in a prospective study including 252 patients on vancomycin monitored via troughs of 10 to 20 mg/L or Bayesian-estimated AUC values of ≥400 mg ▪ hour/L, the likelihood of nephrotoxicity was 8 percent versus 0 to 2 percent, respectively [
         <a href="#rid18">
          18
         </a>
         ]. Among patients with AKI, the median vancomycin trough concentration was 15.7 mg/L and the median AUC was 625 mg ▪ hour/L. Among patients without AKI, the median vancomycin trough concentration was 8.7 mg/L and the median AUC was 423 mg ▪ hour/L.
        </p>
        <p>
         Implementation issues associated with AUC-guided monitoring include the need for staff education, protocol development, consideration of software acquisition, and workflow integration for health care workers, laboratory personnel, and pharmacists. Despite its challenges, this approach to AUC estimation has been successfully adopted by some hospitals in the United States.
        </p>
        <p>
         For treatment of patients with severe MRSA infection and stable kidney function, we favor AUC-guided dosing over trough-guided dosing, to target optimal
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         exposure and reduce the risk of vancomycin-induced nephrotoxicity; this approach is in keeping with the 2020 guidelines published by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Disease Society, and the Society of Infectious Disease Pharmacists [
         <a href="#rid1">
          1
         </a>
         ] and the Canadian Agency for Drugs and Technologies in Health [
         <a href="#rid10">
          10
         </a>
         ]. However, thus far data are lacking to establish the superiority of this approach for treatment outcomes [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p>
         Given the increasing availability and experience with the use of AUC calculators (including Bayesian and non-Bayesian tools), we favor AUC-guided monitoring in patients with severe
         <em>
          S. aureus
         </em>
         infection and stable kidney function; this approach requires involvement of a pharmacist. If AUC-guided monitoring (with AUC calculator and pharmacist involvement) is not feasible, trough-guided monitoring is warranted.
        </p>
        <p>
         AUC-guided dosing should not be used among patients for which data supporting this approach are sparse; these categories include patients with unstable kidney function, patients on renal replacement therapy, patients with nonsevere infections (such as skin and skin structure or urinary tract infection) or non-MRSA infections, and patients with central nervous system infections (ie, meningitis and ventriculitis):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Management of patients with unstable kidney function is discussed below. (See
         <a class="local">
          'Patients with unstable kidney function'
         </a>
         below and
         <a class="local">
          'Trough-guided intermittent dosing'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Management of patients on renal replacement therapy is discussed below. (See
         <a class="local">
          'Patients on renal replacement therapy'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Management of patients with nonsevere or non-
         <em>
          S. aureus
         </em>
         infections is discussed below. (See
         <a class="local">
          'Nonsevere or non-S. aureus infection'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Management of patients with central nervous system infections is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1290.html" rel="external">
          "Initial therapy and prognosis of community-acquired bacterial meningitis in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         For patients with MRSA infection with MIC
         <sub>
          BMD
         </sub>
         ≥2 mcg/mL, alternative therapeutic agents should be considered, since AUC-guided dosing assumes a minimum inhibitory concentration determined by broth microdilution (MIC
         <sub>
          BMD
         </sub>
         )
         <sub>
         </sub>
         of 1 mcg/mL to achieve AUC/MIC
         <sub>
          BMD
         </sub>
         targets. This is discussed further separately. (See
         <a class="medical medical_review" href="/z/d/html/3165.html" rel="external">
          "Staphylococcus aureus bacteremia with reduced susceptibility to vancomycin"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3164.html" rel="external">
          "Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Treatment of bacteremia"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1047419149">
         <span class="h3">
          Intermittent infusion
         </span>
         <span class="headingEndMark">
          —
         </span>
         The approach to II for patients with stable kidney function is described below. The approach to II requires special consideration in the following patient populations:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with obesity (see
         <a class="local">
          'Patients with obesity'
         </a>
         below)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients on renal replacement therapy (see
         <a class="local">
          'Patients on renal replacement therapy'
         </a>
         below)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with unstable kidney function (see
         <a class="local">
          'Patients with unstable kidney function'
         </a>
         below)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1643693301">
         <span class="h4">
          Loading dose
         </span>
         <span class="headingEndMark">
          —
         </span>
         We give a loading dose for patients with known or suspected severe
         <em>
          S. aureus
         </em>
         infection [
         <a href="#rid1">
          1
         </a>
         ]. Use of a loading dose in such patients reduces the likelihood of suboptimal initial
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         exposure. (See
         <a class="local">
          'Severe S. aureus infection'
         </a>
         above.)
        </p>
        <p>
         We administer a
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         loading dose of 20 to 35 mg/kg, based on actual body weight, rounded to the nearest 250 mg increment and not exceeding 3000 mg [
         <a href="#rid1">
          1
         </a>
         ]. Within this range, we use a higher dose for critically ill patients and a lower dose for patients undergoing renal replacement therapy, patients with obesity, and patients receiving vancomycin via CI. (See
         <a class="local">
          'Critical illness'
         </a>
         below and
         <a class="local">
          'Patients on renal replacement therapy'
         </a>
         below and
         <a class="local">
          'Patients with obesity'
         </a>
         below and
         <a class="local">
          'Continuous infusion'
         </a>
         below.)
        </p>
        <p>
         Data on use of
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         loading dose are limited, due to small size, heterogenous populations, and variable dosing practices [
         <a href="#rid45">
          45-48
         </a>
         ]. In one trial including 99 adults presenting to the emergency department with an indication for vancomycin, patients were randomly assigned to receive an initial loading dose (30 mg/kg) or a standard dose (15 mg/kg) [
         <a href="#rid46">
          46
         </a>
         ]. A vancomycin trough of 15 to 20 mg/L was achieved more frequently among patients who received a loading dose than those who received a standard dose (34 versus 3 percent). The study was not powered to detect a difference in other outcomes including mortality or nephrotoxicity.
        </p>
        <p class="headingAnchor" id="H75566955">
         <span class="h4">
          Initial maintenance dose/interval
         </span>
         <span class="headingEndMark">
          —
         </span>
         The initial maintenance dose consists of approximately 15 to 20 mg/kg actual body weight (rounded to the nearest 250 mg). The dosing interval may be determined by either a nomogram  (
         <a class="graphic graphic_table graphicRef60466" href="/z/d/graphic/60466.html" rel="external">
          table 2
         </a>
         ) or utilizing first-order equations based on estimates of creatinine clearance using the Cockcroft-Gault equation (
         <a class="calc calc_professional" href="/z/d/html/13496.html" rel="external">
          calculator 1
         </a>
         ). As an example, a 70 kg patient with normal renal function would receive a dose of 1000 mg to 1250 mg IV every 8 to 12 hours.
        </p>
        <p>
         In settings where AUC-guided dosing is possible, the anticipated AUC, peak concentration, and trough concentration can be estimated prior to administration. Thereafter, adjustments are made based on AUC-guided or trough-guided serum concentration monitoring to establish the subsequent maintenance dose and interval.
        </p>
        <p>
         In general, for most patients with normal kidney function,
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         dosing consists of approximately 15 to 20 mg/kg/dose (based on actual body weight rounded to the nearest 250 mg) every 8 to 12 hours.
        </p>
        <p class="headingAnchor" id="H2461525246">
         <span class="h4">
          Subsequent maintenance dose/interval
         </span>
        </p>
        <p class="headingAnchor" id="H1467468683">
         <span class="h5">
          AUC-guided intermittent dosing
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with severe
         <em>
          S. aureus
         </em>
         infection and stable kidney function, we favor area under the 24-hour time-concentration curve (AUC
         <sub>
          24
         </sub>
         )-guided dosing (when available) to target optimal
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         exposure and reduce the risk of vancomycin-induced nephrotoxicity [
         <a href="#rid1">
          1
         </a>
         ]. (See
         <a class="local">
          'AUC-guided versus trough-guided serum concentration monitoring'
         </a>
         above.)
        </p>
        <p>
         For patients with serious MRSA infections (assuming a
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         MIC
         <sub>
          BMD
         </sub>
         of 1 mcg/mL), a vancomycin AUC of 400 to 600 mg ▪ hour/L should be targeted.
        </p>
        <p>
         Methods for AUC determination and subsequent determination of the dose and interval include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Use of an AUC calculator
         </strong>
         – One approach to AUC-guided dosing involves the use of an AUC calculator (Bayesian or non-Bayesian), together with an individual patient's
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         serum concentrations, to calculate an individualized dosing regimen [
         <a href="#rid49">
          49
         </a>
         ]. This is most often performed by a pharmacist (either outside or integrated within the electronic medical record).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Following administration of the loading dose (see
         <a class="local">
          'Loading dose'
         </a>
         above) and the initial maintenance dose (see
         <a class="local">
          'Initial maintenance dose/interval'
         </a>
         above), two serum
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         concentrations are collected within the first 24 to 48 hours: a peak (at one to two hours after infusion) and a trough (at end of the dosing interval, prior to the next dose) [
         <a href="#rid39">
          39,50-52
         </a>
         ]. While a single trough concentration may be sufficient, further study of this approach is needed [
         <a href="#rid41">
          41
         </a>
         ]. One study demonstrated Bayesian-derived AUC determinations based on single concentrations were associated with have increased variability and reduced correlation to alternate (equation-derived, first-order) methods to determine AUC exposure [
         <a href="#rid53">
          53
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The approach to dose adjustments to achieve the target AUC depends on the type of calculator used.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Use of this approach requires a hospital or health care system to purchase software, provide pharmacist training, and ensure adequate staffing to make daily dose adjustments for individual patients.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Data evaluating use of Bayesian software for AUC-guided monitoring are limited. In one observational study including 123 adults with MRSA bacteremia in which Bayesian methods were used to estimate the daily AUC, the risk of failure (30-day mortality, bacteremia ≥7 days, or recurrent infection) was lowest when the day 1 AUC/
         <sub>
          MICBMD
         </sub>
         ratio exceeded 521 (relative risk [RR] 0.66, 95% CI 0.32-1.33) and the day 2 AUC/
         <sub>
          MICBMD
         </sub>
         ratio exceeded 650 mg ▪ hour/L (RR 0.59, 95% CI 0.29-1.22) [
         <a href="#rid54">
          54
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Use of first-order pharmacokinetic equations
         </strong>
         − An alternative method consists of AUC estimation via first-order PK equations [
         <a href="#rid39">
          39,50
         </a>
         ]. Use of spreadsheet software programmed with the appropriate equations has been described to facilitate such a practice. This reduces the implementation and cost considerations when compared with use of Bayesian software.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Following administration of the loading dose (see
         <a class="local">
          'Loading dose'
         </a>
         above) and the initial maintenance dose (see
         <a class="local">
          'Initial maintenance dose/interval'
         </a>
         above), two serum
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         concentrations are collected, preferably near steady-state (eg, the fourth dose): a trough before the fourth dose and a peak (at one to two hours after infusion of the fourth dose) [
         <a href="#rid39">
          39,55
         </a>
         ]. Use of two concentrations provides AUC determinations that demonstrate favorable correlation and acceptable variability when compared with Bayesian-derived determinations (which also use two serum concentrations) [
         <a href="#rid53">
          53
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         After estimating the AUC
         <sub>
         </sub>
         utilizing serum concentration data, the total daily dose may be revised accordingly to produce proportional changes in the observed AUC [
         <a href="#rid56">
          56,57
         </a>
         ]. This may also facilitate the use of trough-only concentrations for subsequent monitoring [
         <a href="#rid58">
          58
         </a>
         ]. However, this approach only provides a snapshot of the AUC for the sampling period. In addition, for patients who receive multiple dosing regimens within a 24-hour period, it is difficult to estimate the
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         AUC with this approach.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H451906977">
         <span class="h5">
          Trough-guided intermittent dosing
         </span>
         <span class="headingEndMark">
          —
         </span>
         Trough-guided dosing is warranted for management of patients with severe
         <em>
          S. aureus
         </em>
         infection who require
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         therapy in the following circumstances:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Settings where it is not feasible to perform AUC-guided dosing, including where individualized pharmacist involvement may not be available
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with unstable kidney function
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with central nervous system infection (eg, meningitis or ventriculitis), given limited data to support use of AUC-guided dosing in these circumstances
        </p>
        <p>
        </p>
        <p>
         Following administration of the loading dose (see
         <a class="local">
          'Loading dose'
         </a>
         above) and the initial maintenance dose (see
         <a class="local">
          'Initial maintenance dose/interval'
         </a>
         above),
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         serum concentration monitoring is performed.
        </p>
        <p>
         In the setting of stable kidney function (and in the absence of significant renal dysfunction), steady-state
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         serum trough concentrations should be collected prior to the fourth dose following the most recent dose adjustment, within 30 minutes prior to infusion [
         <a href="#rid59">
          59
         </a>
         ]. Dose adjustments should be guided by vancomycin troughs (target 15 to 20 mcg/mL for severe infection), based on careful interpretation of concentration timing, clinical response, tolerability, stability of kidney function, and plans for continued therapy (including need for outpatient antibiotic therapy).
        </p>
        <p>
         In general, for most patients with normal kidney function,
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         dosing consists of approximately 15 to 20 mg/kg/dose (based on actual body weight rounded to the nearest 250 mg) every 8 to 12 hours, not to exceed single doses of 2000 mg unless measured serum trough concentrations are below target concentrations. In the setting of rapid renal clearance (such as in burn patients or in younger patients with normal kidney function), administration of vancomycin every 8 hours may be required to achieve target troughs.
        </p>
        <p class="headingAnchor" id="H538860223">
         <span class="h4">
          Subsequent monitoring
         </span>
         <span class="headingEndMark">
          —
         </span>
         Once the maintenance dose has been established (regardless of the method; eg, AUC-guided or trough-guided dosing), continued serum
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         and creatinine concentrations should be monitored at least weekly in the following circumstances [
         <a href="#rid60">
          60,61
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients receiving
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         beyond the initial empiric stage (eg, longer than 48 to 72 hours)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients at increased risk of nephrotoxicity, such as those with underlying renal dysfunction and use of concomitant nephrotoxic medications
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with fluctuating kidney function, fluctuating fluid balance, hemodynamic instability, critical illness, obesity, or receiving renal replacement therapy
        </p>
        <p>
        </p>
        <p>
         In general, adjustment of the dose (with no adjustment of the dosing interval) will result in proportional change in the serum concentration (assuming drug clearance is in steady state). Therefore, changes in the total daily dose will result in proportional changes in AUC. Each change in the individual dose will alter both peak and trough concentrations proportionately.
        </p>
        <p>
         Adjustment of the dosing interval does not result in proportional change in the trough concentration. The predicted effect of such adjustment requires a calculation. Pharmacists are able to assist in such calculations and to optimize
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         dosing for individual patients.
        </p>
        <p>
         Following dose adjustment, repeat
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         serum concentrations should be measured prior to the fourth dose following the adjustment (in the setting of stable kidney function).
        </p>
        <p class="headingAnchor" id="H518975646">
         <span class="h3">
          Continuous infusion
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most studies of CI used loading doses of 15 to 20 mg/kg, followed by total daily doses of 30 to 40 mg/kg (up to 60 mg/kg) to achieve a target steady-state concentration of 20 to 25 mcg/mL [
         <a href="#rid62">
          62
         </a>
         ]. The desired drug exposure may be achieved by changing the rate of infusion. Use of CI facilitates AUC calculation (eg, a single steady-state concentration multiplied by a factor of 24). However, use of AUC targets in the setting of CI has not been validated.
        </p>
        <p class="headingAnchor" id="H2767727596">
         <span class="h2">
          Nonsevere or non-S. aureus infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         The optimal method of dosing and AUC target for nonsevere or non-
         <em>
          S. aureus
         </em>
         infections is not well established; pending further study, we favor trough-guided dosing. While some hospitals may use AUC-guided monitoring for such patients, the optimal AUC target for nonsevere or non-
         <em>
          S. aureus
         </em>
         infections is not well established.
        </p>
        <p>
         For patients receiving
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         for treatment of nonsevere infection (such as uncomplicated skin and soft tissue infection) who are not on renal replacement therapy, we do not favor routine use of a loading dose (since early therapeutic vancomycin concentrations are not as critical as in patients with severe
         <em>
          S. aureus
         </em>
         infection).
        </p>
        <p>
         For patients with normal renal function,
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         dosing consists of approximately 15 to 20 mg/kg/dose (based on actual body weight rounded to the nearest 250 mg) every 8 to 12 hours, not to exceed single doses of 2000 mg.
        </p>
        <p>
         The initial maintenance dose may also be determined using a nomogram  (
         <a class="graphic graphic_table graphicRef60466" href="/z/d/graphic/60466.html" rel="external">
          table 2
         </a>
         ) including the actual body weight and creatinine clearance (estimated using the Cockcroft-Gault equation (
         <a class="calc calc_professional" href="/z/d/html/13496.html" rel="external">
          calculator 1
         </a>
         )). For patients who will continue
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         for ≥3 days, we favor trough-based maintenance dose adjustments with target trough concentrations of 10 to 15 mcg/mL. For patients who receive vancomycin for &lt;3 days (in the setting of stable kidney function and absence of other risk factors for altered vancomycin kinetics), vancomycin concentration monitoring is often omitted; the value of such monitoring prior to achieving steady state (usually around treatment day 2 to 3) is uncertain.
        </p>
        <p>
         Once the maintenance dose has been established,
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         serum concentration monitoring is performed as described above. (See
         <a class="local">
          'Subsequent monitoring'
         </a>
         above.)
        </p>
        <p>
         For patients with severe infections due to pathogens other than
         <em>
          S. aureus
         </em>
         , data regarding the relationship between
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         exposure and clinical efficacy are sparse. The approach to vancomycin dosing for treatment of infectious endocarditis is addressed in consensus guidelines and is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2152.html" rel="external">
          "Antimicrobial therapy of left-sided native valve endocarditis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2141.html" rel="external">
          "Antimicrobial therapy of prosthetic valve endocarditis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H335267107">
         <span class="h1">
          SPECIAL POPULATIONS
         </span>
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h2">
          Patients with obesity
         </span>
         <span class="headingEndMark">
          —
         </span>
         Obesity (defined as a body mass index of ≥30 kg/m
         <sup>
          2
         </sup>
         ) may be associated with an increased risk of vancomycin-induced nephrotoxicity, due to supratherapeutic exposure resulting from dosing calculated using actual body weight [
         <a href="#rid63">
          63,64
         </a>
         ].
        </p>
        <p>
         Studies evaluating
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         kinetics in patients with obesity have reported mathematical relationships between patient-specific parameters (sex, body weight, and serum creatinine) and vancomycin clearance [
         <a href="#rid11">
          11,65
         </a>
         ]. Such estimates are useful in both area under the 24-hour time-concentration curve (AUC)- and trough-guided strategies to determine initial maintenance doses and dosing interval.
        </p>
        <p>
         The decision to administer a
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         loading dose should be guided by infection severity (and therefore urgency to achieve a targeted concentration). If a loading dose is indicated, we administer 20 to 25 mg/kg (rounded to the nearest 250 mg with a maximum of 3000 mg) [
         <a href="#rid65">
          65
         </a>
         ]. Within this range, we use a higher dose for critically ill patients.
        </p>
        <p>
         The approach to determination of a maintenance dose for patients with obesity is similar to the approach for patients without obesity. (See
         <a class="local">
          'Subsequent maintenance dose/interval'
         </a>
         above.)
        </p>
        <p>
         In general, for most patients with obesity and normal kidney function,
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         dosing consists of approximately 30 to 45 mg/kg per day (based on actual body weight) in two or three divided doses [
         <a href="#rid66">
          66
         </a>
         ]. In general, the total daily dose should not exceed 4500 mg/day unless justified by serum concentration monitoring [
         <a href="#rid1">
          1,65
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3345648004">
         <span class="h2">
          Patients on renal replacement therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Significant alterations in
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         distribution and elimination can occur in patients receiving renal replacement therapy. Consideration must be given to time between the prior vancomycin dose and dialysis, intradialytic or postdialysis administration, method of dialysis (and associated dialyzer permeability), and dialysis frequency.
        </p>
        <p>
         We give a loading dose for patients on receiving renal replacement therapy (regardless of the pathogen or severity of infection), to optimize the potential for early achievement of therapeutic concentrations. Data on use of a loading dose for patients on renal replacement are limited to modeling studies to evaluate the optimal approach to achieving target troughs [
         <a href="#rid67">
          67-69
         </a>
         ].
        </p>
        <p>
         Data for AUC-guided dosing in patients requiring renal replacement therapy are limited. In one report, predialysis serum concentrations ranging between 10 to 20 mcg/mL (a common target in this population) resulted in suboptimal AUC exposures in many patients (range 250 to 450 mg ▪ hour/L) [
         <a href="#rid70">
          70
         </a>
         ]. Therefore, further study is needed to optimize AUC-guided dosing strategies in this population.
        </p>
        <p class="headingAnchor" id="H3534356324">
         <span class="h3">
          Intermittent hemodialysis
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          Vancomycin
         </a>
         dosing requirements in patients requiring chronic intermittent hemodialysis is dependent largely on the dialyzer permeability. High-flux intermittent (three- to four-hour sessions performed three times weekly) hemodialysis is commonly used for patients requiring chronic hemodialysis and is the most efficient at vancomycin drug removal. A three to four hour dialysis session using a high-flux membrane can reduce predialysis serum concentrations of vancomycin by up to 50 percent.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          Vancomycin
         </a>
         dosing should be based on actual body weight at the time of drug administration [
         <a href="#rid1">
          1
         </a>
         ]. A dosing strategy for such patients (loading dose followed by maintenance dosing, as described in the 2020 vancomycin dosing guidelines) is as follows [
         <a href="#rid1">
          1
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients receiving
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         after dialysis, the initial (loading) dose consists of 25 mg/kg, followed by a maintenance dose (given after subsequent dialysis sessions) of 10 mg/kg (high dialyzer permeability) or 7.5 mg/kg (low dialyzer permeability). The loading dose may be reduced (to 20 to 25 mg/kg) if the next dialysis session is anticipated within 24 hours.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients receiving intradialytic
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         , the approach depends on the dialyzer permeability. In the setting of high dialyzer permeability (ie, high-flux dialyzer), the initial (loading) dose consists of 35 mg/kg followed by a maintenance dose of 10 to 15 mg/kg. In the setting of low dialyzer permeability (ie, low-flux dialyzer), the loading dose consists of 30 mg/kg, followed by an initial maintenance dose of 7.5 to 10 mg/kg [
         <a href="#rid1">
          1
         </a>
         ]. Doses are rounded to the nearest 250 mg.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Maintenance dosing is most often administered during the final hour of the dialysis session to expedite discharge from the dialysis unit. Approximately 20 to 40 percent of a
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         dose administered during dialysis is removed [
         <a href="#rid71">
          71,72
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Predialysis serum concentration monitoring facilities the determination of subsequent
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         doses while avoiding postdialysis rebound concentrations, which can occur up to three to six hours after a session [
         <a href="#rid73">
          73
         </a>
         ].
         <em>
         </em>
         After the initial maintenance dose is calculated, subsequent maintenance doses are determined based on serum concentrations obtained immediately prior to dialysis [
         <a href="#rid74">
          74
         </a>
         ]. Predialysis serum concentration monitoring should be performed for two dialysis sessions following an initial maintenance regimen, for any maintenance dose modifications, and then at least weekly thereafter. Dose adjustments should be made as summarized in the table  (
         <a class="graphic graphic_table graphicRef97965" href="/z/d/graphic/97965.html" rel="external">
          table 3
         </a>
         ).
        </p>
        <p>
         In the typical three times-weekly hemodialysis schedule, a dose increase of 25 percent is usually needed for the three-day interdialytic period to maintain sufficient
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         concentrations on the third day [
         <a href="#rid67">
          67,68,75
         </a>
         ].
        </p>
        <p>
         Intermittent hemodialysis may be utilized more frequently (up to daily) at slower blood and dialysate flow rates and longer durations (such as 6 to 12 hours per day) in attempts to facilitate outpatient dialysis and/or minimize the undesirable hemodynamic effects. Since the time to the next hemodialysis session is reduced (relative to traditional intermittent hemodialysis of three times weekly), a reduced loading dose of 20 mg/kg can be administered in such settings. Maintenance doses depend on timing of administration but up to 15 mg/kg can be administered initially if given within the final 60 to 90 minutes of the dialysis session [
         <a href="#rid1">
          1
         </a>
         ]. Serum concentration monitoring predialysis should be conducted as described above to determine dose adjustments.
        </p>
        <p class="headingAnchor" id="H419376098">
         <span class="h3">
          Peritoneal dialysis
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients on peritoneal dialysis requiring systemic administration of
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         for treatment of infection outside the peritoneal cavity, an intravenous loading dose of 20 to 25 mg/kg (rounded to the nearest 250 mg increment) should be administered. A vancomycin serum concentration should be obtained approximately 48 to 72 hours after the loading dose, and subsequent doses (15 to 20 mg/kg intravenously) should be administered based on attainment of goal serum concentrations.
        </p>
        <p>
         Patients with peritonitis may best be treated via intraperitoneal administration of
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         . This is discussed further separately. (See
         <a class="medical medical_review" href="/z/d/html/1882.html" rel="external">
          "Microbiology and therapy of peritonitis in peritoneal dialysis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1187413911">
         <span class="h3">
          Continuous renal replacement
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients receiving continuous renal replacement therapy (CRRT),
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         clearance is relatively constant over the dosing interval and is closely related to the rate of ultrafiltrate/dialysate flow. Such patients may receive intermittent or continuous infusions (CIs) of vancomycin.
        </p>
        <p>
         For patients receiving CRRT at conventional effluent rates (20 to 25 mL/kg/hour) managed with intermittent dosing, the
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         loading dose consists of 20 to 25 mg/kg (actual body weight), followed by an initial maintenance dose of 7.5 to 10 mg/kg every 12 hours [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         Subsequent maintenance dosing should be based on serum concentration monitoring conducted within the first 24 hours to ensure the AUC target is met [
         <a href="#rid76">
          76
         </a>
         ]. The optimal pharmacokinetic targets among patients receiving CRRT are uncertain; studies validating the AUC goal of 400 to 600 mg ▪ hour/L used in other settings have not been conducted in this population. Nonetheless, the maintenance doses described above aim to reach this AUC target. (See
         <a class="local">
          'AUC-guided intermittent dosing'
         </a>
         above.)
        </p>
        <p>
         In patients with fluid overload, the need for dosing reductions should be anticipated as the volume status normalizes.
        </p>
        <p>
         CIs of
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         may be useful in patients receiving CRRT. Issues related to CI of vancomycin are discussed above [
         <a href="#rid77">
          77,78
         </a>
         ]. (See
         <a class="local">
          'Continuous infusion'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H2784753715">
         <span class="h2">
          Patients with unstable kidney function
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with unstable kidney function (either worsening or improving) are perhaps the most challenging population for determination of an optimal
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         dosing schedule, due to fluctuations in drug distribution and elimination.
        </p>
        <p>
         For such patients, a strategy referred to as "dose per concentration" is employed. Target serum concentrations consist of 15 to 20 mcg/mL for severe infection and 10 to 15 mcg/mL for nonsevere infection.
        </p>
        <p>
         For patients with severe
         <em>
          S. aureus
         </em>
         infection, a loading dose of 20 to 25 mg/kg may be given. For patients with nonsevere or non-
         <em>
          S. aureus
         </em>
         infection, the initial dose is administered as outlined in the nomogram  (
         <a class="graphic graphic_table graphicRef60466" href="/z/d/graphic/60466.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
         Following the initial/loading dose, a serum
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         concentration is obtained at 12 to 24 hours. If the concentration is above the target concentration, a repeat concentration is obtained the following day; once the concentration is at or below the target concentration, a repeat dose (15 to 20 mg/kg rounded to the nearest 250 mg increment) is administered. If the concentration is below the target concentration, a repeat dose (15 to 20 mg/kg rounded to the nearest 250 mg increment) is administered. Therefore, the frequency of drug administration is guided by repeated serum concentration monitoring.
        </p>
        <p class="headingAnchor" id="H1163432128">
         <span class="h2">
          Critical illness
         </span>
         <span class="headingEndMark">
          —
         </span>
         Among patients with critical illness, increases in the volume of distribution (and the resulting increase in clearance) have been described [
         <a href="#rid79">
          79
         </a>
         ]. In such patients, higher
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         loading doses (25 to 30 mg/kg) may be required to achieve optimal vancomycin exposure.
        </p>
        <p class="headingAnchor" id="H1269346913">
         <span class="h1">
          ADVERSE EFFECTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Adverse effects of parenteral
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         include rash (due to infusion reaction or true vancomycin sensitivity), infusion-related reactions, nephrotoxicity, and ototoxicity. (See
         <a class="medical medical_review" href="/z/d/html/2083.html" rel="external">
          "Vancomycin hypersensitivity"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H820785050">
         <span class="h2">
          Infusion reaction
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Phlebitis
         </strong>
         – Intravenous administration of
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         has been associated with low rates of infusion-site phlebitis, given its acidic pH. Administration of vancomycin via central venous access may minimize such reactions but is not required. Additional strategies that may reduce the likelihood of phlebitis include reducing the infusion rate, diluting the drug in higher volumes of fluid, and the use of continuous infusion [
         <a href="#rid80">
          80
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Rash
         </strong>
         – Vancomycin-induced infusion reaction associated with rash (formerly termed 'Red man syndrome') is a histamine-mediated reaction observed during or immediately following
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         infusion [
         <a href="#rid81">
          81
         </a>
         ]. Dermatologic findings may include erythema that can be confluent or blotchy, typically involving the head and neck but also the trunk, extremities, and palms or soles or urticaria that can be localized or diffuse.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The reaction may be reduced or eliminated by avoiding excessive
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         doses, prolonging the infusion time (eg, administering the drug at a rate of no more than 500 mg/hour), and administration of antihistamines (prior to or during infusion) [
         <a href="#rid82">
          82
         </a>
         ]. Some patients require an even slower infusion rate or continuous infusion dosing [
         <a href="#rid83">
          83
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Issues related to infusion reaction and
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         hypersensitivity reactions are discussed further separately. (See
         <a class="medical medical_review" href="/z/d/html/2083.html" rel="external">
          "Vancomycin hypersensitivity", section on 'Vancomycin infusion reaction'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3209587989">
         <span class="h2">
          Acute kidney injury
         </span>
         <span class="headingEndMark">
          —
         </span>
         Acute kidney injury (AKI) is an important adverse effect of
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         . The mechanism of vancomycin nephrotoxicity involves apoptosis induced by accumulation of drug in proximal tubular epithelial cells.
        </p>
        <p>
         Factors influencing risk of AKI include dose, host-related factors (increased weight, pre-existing renal dysfunction, and critical illness), and concurrent administration of nephrotoxic agents (such as aminoglycosides, loop diuretics, amphotericin B, intravenous contrast dye, and vasopressors) [
         <a href="#rid84">
          84,85
         </a>
         ].
        </p>
        <p>
         Most studies define vancomycin-associated AKI as an increase in the serum creatinine concentration by ≥0.5 mg/dL, an increase in serum creatinine by 50 percent from baseline in consecutive daily readings, or a decrease in calculated creatinine clearance by 50 percent from baseline on two consecutive days, in the absence of an alternative explanation [
         <a href="#rid1">
          1
         </a>
         ]. A more sensitive threshold, an increase in serum creatinine of ≥0.3 mg/dL over a 48-hour period, has also been proposed as an indicator of vancomycin-associated AKI [
         <a href="#rid86">
          86,87
         </a>
         ].
        </p>
        <p>
         The incidence of vancomycin-associated AKI is variable. In one meta-analysis including 15 studies, the prevalence of vancomycin-associated AKI ranged from 5 to 43 percent [
         <a href="#rid87">
          87-91
         </a>
         ]. Similarly, in another meta-analysis including 13 studies (randomized trials and cohort studies) comparing patients treated with
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         with patients treated with a nonglycopeptide antibiotic, the relative risk of AKI with vancomycin was 2.45 (95% CI 1.69-3.55) [
         <a href="#rid92">
          92
         </a>
         ]. Most episodes of AKI developed between 4 and 17 days after initiation of therapy.
        </p>
        <p class="headingAnchor" id="H3494741285">
         <span class="h3">
          Impact of dose
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several retrospective studies have attempted to quantify the relationship between
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         exposure and likelihood of AKI [
         <a href="#rid93">
          93,94
         </a>
         ]. The available data suggest that the risk of AKI increases as a function of the vancomycin trough concentration, especially when the trough is maintained within the 15 to 20 mg/L [
         <a href="#rid25">
          25,84,87,93,95
         </a>
         ] range generally targeted for severe infections. Similarly, data suggest that the risk of AKI increases as the area under the 24-hour time-concentration curve (AUC) increases, especially when the daily AUC exceeds 650 to 1300 [
         <a href="#rid1">
          1,41,94
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a study including 166 patients treated with
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         , the likelihood of AKI was 2.5-fold greater among patients with AUC values above 1300 compared with patients with lower values (30.8 versus 13.1 percent) [
         <a href="#rid93">
          93
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a study including 165 patients with methicillin-resistant
         <em>
          Staphylococcus aureus
         </em>
         (MRSA) bacteremia, AKI increased along the day 2 AUC continuum in a stepwise manner, and patients with day 2 AUC values ≥793 were at the greatest risk for AKI [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a post-hoc analysis of a trial evaluating the efficacy and safety of combination therapy with
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         plus antistaphylococcal beta-lactams for treatment of MRSA bacteremia, vancomycin AUC was an independent risk factor for AKI (in addition to flucloxacillin co-administration) [
         <a href="#rid96">
          96
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1525130526">
         <span class="h3">
          Coadministration with other drugs
         </span>
         <span class="headingEndMark">
          —
         </span>
         Coadministration of
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         with other nephrotoxic agents is associated with increased risk of AKI; these include loop diuretics, aminoglycosides, amphotericin B, intravenous contrast dye, vasopressors, and hydrophobic beta-lactams (notably
         <a class="drug drug_general" data-topicid="9777" href="/z/d/drug information/9777.html" rel="external">
          piperacillin-tazobactam
         </a>
         and flucloxacillin), which may demonstrate proximal tubular accumulation [
         <a href="#rid84">
          84,85,96,97
         </a>
         ]. The degree of beta-lactam hydrophobicity appears to correlate with the relative added risk of renal injury when combined with vancomycin [
         <a href="#rid96">
          96,98,99
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Aminoglycosides
         </strong>
         – Nephrotoxicity associated with coadministration of
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         and an aminoglycoside is well established. The incidence of acute renal failure in this setting may be as high as 20 to 30 percent [
         <a href="#rid88">
          88,91,100
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Beta-lactams –
         </strong>
         The risk of nephrotoxicity associated with coadministration of
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         and various beta-lactam agents is heterogeneous, and high-quality data are sparse. It has been suggested that the risk may correlate with beta-lactam hydrophilicity, presumably due to proximal tubular accumulation and augmenting vancomycin cellular stress. Based on this relationship, hydrophobic beta-lactams (such as
         <a class="drug drug_general" data-topicid="9775" href="/z/d/drug information/9775.html" rel="external">
          piperacillin
         </a>
         , flucloxacillin,
         <a class="drug drug_general" data-topicid="9674" href="/z/d/drug information/9674.html" rel="external">
          nafcillin
         </a>
         , and
         <a class="drug drug_general" data-topicid="9724" href="/z/d/drug information/9724.html" rel="external">
          oxacillin
         </a>
         ) would pose higher risks of augmenting vancomycin nephrotoxicity compared to hydrophilic beta-lactams (such as most cephalosporins, carbapenems, tazobactam, and
         <a class="drug drug_general" data-topicid="8737" href="/z/d/drug information/8737.html" rel="external">
          ampicillin
         </a>
         ) [
         <a href="#rid99">
          99
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Coadministration of
         </strong>
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         <strong>
          and antipseudomonal beta-lactams
         </strong>
         – For patients who warrant prolonged coadministration of vancomycin with an antipseudomonal beta-lactam (such as
         <a class="drug drug_general" data-topicid="9777" href="/z/d/drug information/9777.html" rel="external">
          piperacillin-tazobactam
         </a>
         or
         <a class="drug drug_general" data-topicid="9215" href="/z/d/drug information/9215.html" rel="external">
          cefepime
         </a>
         ), the risks of acute kidney injury should be considered carefully when selecting an antibiotic regimen. Clinical factors warranting consideration include baseline renal function and whether more than one potentially nephrotoxic agent may be needed.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         In some retrospective studies, coadministration of
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         and
         <a class="drug drug_general" data-topicid="9777" href="/z/d/drug information/9777.html" rel="external">
          piperacillin-tazobactam
         </a>
         (relative to vancomycin monotherapy and coadministration of vancomycin with other beta-lactams, notably
         <a class="drug drug_general" data-topicid="9215" href="/z/d/drug information/9215.html" rel="external">
          cefepime
         </a>
         ) has been associated with an odds ratio for AKI of up to 3.5 [
         <a href="#rid101">
          101-105
         </a>
         ]. While studies evaluating combination therapy with vancomycin and cephalosporins generally suggest a low potential for added risk of nephrotoxicity, many are limited by retrospective design, small sample size, and suboptimal assessment for nephrotoxicity [
         <a href="#rid106">
          106-109
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         In contrast, an open-label randomized trial (ACORN) including more than 1900 patients treated with
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         and either
         <a class="drug drug_general" data-topicid="9777" href="/z/d/drug information/9777.html" rel="external">
          piperacillin-tazobactam
         </a>
         or
         <a class="drug drug_general" data-topicid="9215" href="/z/d/drug information/9215.html" rel="external">
          cefepime
         </a>
         reported the incidence of acute kidney injury (KDIGO stage 3  (
         <a class="graphic graphic_table graphicRef83168" href="/z/d/graphic/83168.html" rel="external">
          table 4
         </a>
         )) by day 14 was comparable between the groups (approximately 7 percent) [
         <a href="#rid110">
          110
         </a>
         ]. However, the median duration of antibiotic treatment was only 3 days, which is far shorter than the observed risk of AKI of vancomycin plus piperacillin-tazobactam, limiting the study's generalizability. In addition, there was substantial crossover of antibiotic received (approximately 18 percent in both groups) [
         <a href="#rid111">
          111
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         It has been hypothesized that the effects of combination treatment with
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         and
         <a class="drug drug_general" data-topicid="9777" href="/z/d/drug information/9777.html" rel="external">
          piperacillin-tazobactam
         </a>
         may reflect pseudotoxicity; use of alternate biomarkers (such as cystatin C) rather than serum creatinine may be more accurate indicators of nephrotoxicity [
         <a href="#rid112">
          112
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Coadministration of
         </strong>
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         <strong>
          and antistaphylococcal beta-lactams
         </strong>
         – In a randomized trial (CAMERA-2) including 111 patients with MRSA bacteremia treated with vancomycin and either flucloxacillin or
         <a class="drug drug_general" data-topicid="9288" href="/z/d/drug information/9288.html" rel="external">
          cloxacillin
         </a>
         , the study was stopped early due to nephrotoxicity [
         <a href="#rid97">
          97,98
         </a>
         ]. Among 27 patients treated with vancomycin and
         <a class="drug drug_general" data-topicid="9214" href="/z/d/drug information/9214.html" rel="external">
          cefazolin
         </a>
         , no elevated risk of AKI was observed.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Issues related to treatment of MRSA are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3164.html" rel="external">
          "Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Treatment of bacteremia"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3726541159">
         <span class="h3">
          Management
         </span>
         <span class="headingEndMark">
          —
         </span>
         It can be difficult to distinguish between drug-induced AKI and other causes of AKI including acute interstitial nephritis. Development of AKI in the setting of
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         therapy should prompt discontinuation of the drug.
        </p>
        <p>
        </p>
        <p>
         Data regarding timeframe for recovery from vancomycin-induced AKI are confounded by presence of additional risk factors for AKI. In one review, improvement or resolution was noted in approximately three-quarters of patients [
         <a href="#rid113">
          113
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2072386946">
         <span class="h2">
          Ototoxicity
         </span>
         <span class="headingEndMark">
          —
         </span>
         Ototoxicity has been observed in association with
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         administration; ototoxicity attributable to vancomycin should prompt discontinuation of the drug [
         <a href="#rid114">
          114,115
         </a>
         ]. Potential risk factors for vancomycin-induced ototoxicity include pre-existing hearing abnormalities and underlying renal dysfunction [
         <a href="#rid100">
          100,116,117
         </a>
         ].
        </p>
        <p>
         Ototoxicity associated with
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         is more common in older patients. In one report including 89 patients who underwent audiograms after an average of 27 days of vancomycin administration, high-frequency hearing loss was observed among patients &gt;53 years of age in 19 percent of cases; no hearing loss was observed among patients &lt;53 years of age [
         <a href="#rid115">
          115
         </a>
         ]. Another study including 130 newborns who received vancomycin and were followed with audiology screening demonstrated no association between vancomycin and ototoxicity [
         <a href="#rid118">
          118
         </a>
         ].
        </p>
        <p>
         In the absence of tinnitus or ataxia, clinical detection of
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         ototoxicity is challenging; in the absence of audiometric testing, high-frequency hearing loss may not be detected and when it occurs, reversibility is unknown. In addition, older adults at greatest risk often suffer high-frequency hearing loss in the absence of vancomycin therapy.
        </p>
        <p>
         Data regarding the natural history of vancomycin-induced ototoxicity are limited; it is generally considered reversible in most cases [
         <a href="#rid116">
          116
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2370328391">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/110550.html" rel="external">
          "Society guideline links: Management of
          <i>
           Staphylococcus aureus
          </i>
          infection"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H22">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dosing approach
         </strong>
         – The approach to
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         dosing in adults depends on the pathogen, the type and severity of infection, and patient factors including weight and kidney function  (
         <a class="graphic graphic_table graphicRef128911" href="/z/d/graphic/128911.html" rel="external">
          table 1
         </a>
         ). Vancomycin is usually administered intermittently; in certain circumstances, continuous infusion may be a useful alternative. (See
         <a class="local">
          'Introduction'
         </a>
         above and
         <a class="local">
          'Intermittent infusion'
         </a>
         above and
         <a class="local">
          'Continuous infusion'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Severe
         </strong>
         <strong>
          <em>
           Staphylococcus aureus
          </em>
         </strong>
         <strong>
          infection
         </strong>
         – For patients with known or suspected severe
         <em>
          S. aureus
         </em>
         infection (including bacteremia, endocarditis, osteomyelitis, prosthetic joint infection, pneumonia warranting hospitalization, infection involving the central nervous system, and/or critical illness) and stable kidney function, our approach to
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         dosing is as follows (see
         <a class="local">
          'Severe S. aureus infection'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Loading dose
         </strong>
         – We suggest administration of a loading dose (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ), to reduce the likelihood of suboptimal initial
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         exposure. We give a loading dose of 20 to 35 mg/kg (based on actual body weight). (See
         <a class="local">
          'Loading dose'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Initial maintenance dose
         </strong>
         – The initial maintenance dose consists of 15 to 20 mg/kg actual body weight (rounded to the nearest 250 mg); the dosing interval is determined by a nomogram  (
         <a class="graphic graphic_table graphicRef60466" href="/z/d/graphic/60466.html" rel="external">
          table 2
         </a>
         ). In general, for most patients with normal kidney function,
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         dosing consists of approximately 15 to 20 mg/kg/dose (based on actual body weight rounded to the nearest 250 mg) every 8 to 12 hours. (See
         <a class="local">
          'Initial maintenance dose/interval'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Stable kidney function: AUC-guided dosing
         </strong>
         – For subsequent maintenance dosing in patients with stable kidney function, we suggest area under the 24-hour time-concentration curve (AUC)-guided dosing if such an option is available (rather than trough-guided dosing) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ), to target optimal
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         exposure and reduce the risk of vancomycin-induced nephrotoxicity. This approach requires the assistance of a pharmacist. The optimal pharmacokinetic/pharmacodynamic efficacy target is considered to be an AUC/minimum inhibitory concentration determined by broth microdilution ratio of 400 to 600 mg ▪ hour/L. (See
         <a class="local">
          'Subsequent maintenance dose/interval'
         </a>
         above and
         <a class="local">
          'Pharmacokinetic/pharmacodynamic target'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         The AUC-guided regimen is established using an AUC calculator (Bayesian or non-Bayesian) together with two serum
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         concentrations collected within the first 24 to 48 hours.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         If an AUC calculator is not available, the subsequent regimen is calculated using first-order pharmacokinetic equations and two serum
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         concentrations collected near steady-state. (See
         <a class="local">
          'AUC-guided intermittent dosing'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         The approach to dose adjustments to achieve the target AUC depends on the type of calculator used.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Unstable kidney function: Trough-guided dosing
         </strong>
         – For patients with unstable kidney function (either worsening or improving) and in settings where it is not feasible to perform AUC-guided dosing, trough-guided dosing is warranted. After the loading dose, the initial maintenance dose is determined using a nomogram  (
         <a class="graphic graphic_table graphicRef60466" href="/z/d/graphic/60466.html" rel="external">
          table 2
         </a>
         ). Thereafter, the subsequent regimen is guided by a serum
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         trough concentration collected near steady state (target 15 to 20 mcg/mL). (See
         <a class="local">
          'Trough-guided intermittent dosing'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nonsevere
         </strong>
         <strong>
          <em>
           S. aureus
          </em>
         </strong>
         <strong>
          infection
         </strong>
         – For patients with nonsevere
         <em>
          S. aureus
         </em>
         infection (such as uncomplicated skin and soft tissue infection), our approach to
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         dosing is as follows (see
         <a class="local">
          'Nonsevere or non-S. aureus infection'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         We suggest not administering loading dose (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ), since early therapeutic
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         concentrations are not as critical in patients with nonsevere infection. The initial dose may be determined using a nomogram  (
         <a class="graphic graphic_table graphicRef60466" href="/z/d/graphic/60466.html" rel="external">
          table 2
         </a>
         ) including the actual body weight and creatinine clearance (estimated using the Cockcroft-Gault equation (
         <a class="calc calc_professional" href="/z/d/html/13496.html" rel="external">
          calculator 1
         </a>
         )). Thereafter, for patients who will continue vancomycin for ≥3 days, the subsequent regimen is guided by a serum vancomycin trough concentration collected at steady state (target 10 to 15 mcg/mL).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other pathogens
         </strong>
         – For patients with severe infections due to pathogens other than
         <em>
          S. aureus
         </em>
         , data regarding the relationship between
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         exposure and clinical efficacy are sparse. The approach to vancomycin dosing for treatment of infectious endocarditis is addressed in consensus guidelines; this is discussed separately. (See
         <a class="local">
          'Nonsevere or non-S. aureus infection'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/2152.html" rel="external">
          "Antimicrobial therapy of left-sided native valve endocarditis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2141.html" rel="external">
          "Antimicrobial therapy of prosthetic valve endocarditis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patients on renal replacement therapy
         </strong>
         – For patients on renal replacement therapy, we suggest use of a loading dose (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). The initial regimen depends on the timing of
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         administration and the dialyzer permeability. Subsequent maintenance doses are determined based on serum concentrations obtained immediately prior to dialysis  (
         <a class="graphic graphic_table graphicRef97965" href="/z/d/graphic/97965.html" rel="external">
          table 3
         </a>
         ). (See
         <a class="local">
          'Patients on renal replacement therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adverse effects
         </strong>
         – Adverse effects of parenteral
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         include rash (due to infusion reaction or true vancomycin sensitivity), infusion-related reactions, nephrotoxicity, and ototoxicity. (See
         <a class="local">
          'Adverse effects'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Coadministration with other drugs
         </strong>
         – Coadministration of
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         with other nephrotoxic agents is associated with increased risk of acute kidney injury. The risk of nephrotoxicity associated with administration of vancomycin with
         <a class="drug drug_general" data-topicid="9777" href="/z/d/drug information/9777.html" rel="external">
          piperacillin-tazobactam
         </a>
         is uncertain. Clinical factors warranting consideration include baseline renal function and whether more than one potentially nephrotoxic agent may be needed. For patients who warrant prolonged coadministration of vancomycin with an antipseudomonal agent, the risks of acute kidney injury should be considered carefully when selecting an antibiotic regimen. (See
         <a class="local">
          'Coadministration with other drugs'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Rybak MJ, Le J, Lodise TP, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2020; 77:835.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matzke GR, McGory RW, Halstenson CE, Keane WF. Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimicrob Agents Chemother 1984; 25:433.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moellering RC Jr, Krogstad DJ, Greenblatt DJ. Vancomycin therapy in patients with impaired renal function: a nomogram for dosage. Ann Intern Med 1981; 94:343.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lake KD, Peterson CD. A simplified dosing method for initiating vancomycin therapy. Pharmacotherapy 1985; 5:340.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pryka RD, Rodvold KA, Erdman SM. An updated comparison of drug dosing methods. Part IV: Vancomycin. Clin Pharmacokinet 1991; 20:463.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lodise TP, Drusano G. Vancomycin Area Under the Curve-Guided Dosing and Monitoring for Adult and Pediatric Patients With Suspected or Documented Serious Methicillin-Resistant Staphylococcus aureus Infections: Putting the Safety of Our Patients First. Clin Infect Dis 2021; 72:1497.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jorgensen SCJ, Spellberg B, Shorr AF, Wright WF. Should Therapeutic Drug Monitoring Based on the Vancomycin Area Under the Concentration-Time Curve Be Standard for Serious Methicillin-Resistant Staphylococcus aureus Infections?-No. Clin Infect Dis 2021; 72:1502.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dilworth TJ, Schulz LT, Rose WE. Vancomycin Advanced Therapeutic Drug Monitoring: Exercise in Futility or Virtuous Endeavor to Improve Drug Efficacy and Safety? Clin Infect Dis 2021; 72:e675.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rodvold KA. 60 Plus Years Later and We Are Still Trying to Learn How to Dose Vancomycin. Clin Infect Dis 2020; 70:1546.
          </a>
         </li>
         <li class="breakAll">
          Vancomycin Therapeutic Drug Monitoring for Serious Methicillin-Resistant Staphylococcus aureus Infections. Ottawa: CADTH; 2020 September. https://www.cadth.ca/sites/default/files/hta-he/ha0006-vancomycin-fca-final.pdf (Accessed on June 29, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rodvold KA, Blum RA, Fischer JH, et al. Vancomycin pharmacokinetics in patients with various degrees of renal function. Antimicrob Agents Chemother 1988; 32:848.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Skhirtladze K, Hutschala D, Fleck T, et al. Impaired target site penetration of vancomycin in diabetic patients following cardiac surgery. Antimicrob Agents Chemother 2006; 50:1372.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cruciani M, Gatti G, Lazzarini L, et al. Penetration of vancomycin into human lung tissue. J Antimicrob Chemother 1996; 38:865.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lin Wu FL, Liu SS, Yang TY, et al. A Larger Dose of Vancomycin Is Required in Adult Neurosurgical Intensive Care Unit Patients Due to Augmented Clearance. Ther Drug Monit 2015; 37:609.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet 2004; 43:925.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Song KH, Kim HB, Kim HS, et al. Impact of area under the concentration-time curve to minimum inhibitory concentration ratio on vancomycin treatment outcomes in methicillin-resistant Staphylococcus aureus bacteraemia. Int J Antimicrob Agents 2015; 46:689.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kullar R, Davis SL, Levine DP, Rybak MJ. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets. Clin Infect Dis 2011; 52:975.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Neely MN, Kato L, Youn G, et al. Prospective Trial on the Use of Trough Concentration versus Area under the Curve To Determine Therapeutic Vancomycin Dosing. Antimicrob Agents Chemother 2018; 62.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zasowski EJ, Murray KP, Trinh TD, et al. Identification of Vancomycin Exposure-Toxicity Thresholds in Hospitalized Patients Receiving Intravenous Vancomycin. Antimicrob Agents Chemother 2018; 62.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lodise TP, Rosenkranz SL, Finnemeyer M, et al. The Emperor's New Clothes: PRospective Observational Evaluation of the Association Between Initial VancomycIn Exposure and Failure Rates Among ADult HospitalizEd Patients With Methicillin-resistant Staphylococcus aureus Bloodstream Infections (PROVIDE). Clin Infect Dis 2020; 70:1536.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Casapao AM, Lodise TP, Davis SL, et al. Association between vancomycin day 1 exposure profile and outcomes among patients with methicillin-resistant Staphylococcus aureus infective endocarditis. Antimicrob Agents Chemother 2015; 59:2978.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jeffres MN, Isakow W, Doherty JA, et al. Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices. Chest 2006; 130:947.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moise PA, Sakoulas G, Forrest A, Schentag JJ. Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2007; 51:2582.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sakoulas G, Moise-Broder PA, Schentag J, et al. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004; 42:2398.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hidayat LK, Hsu DI, Quist R, et al. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006; 166:2138.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lodise TP, Graves J, Evans A, et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 2008; 52:3315.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mohr JF, Murray BE. Point: Vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2007; 44:1536.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wysocki M, Delatour F, Faurisson F, et al. Continuous versus intermittent infusion of vancomycin in severe Staphylococcal infections: prospective multicenter randomized study. Antimicrob Agents Chemother 2001; 45:2460.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Akers KS, Cota JM, Chung KK, et al. Serum vancomycin levels resulting from continuous or intermittent infusion in critically ill burn patients with or without continuous renal replacement therapy. J Burn Care Res 2012; 33:e254.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saugel B, Nowack MC, Hapfelmeier A, et al. Continuous intravenous administration of vancomycin in medical intensive care unit patients. J Crit Care 2013; 28:9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hanrahan TP, Harlow G, Hutchinson J, et al. Vancomycin-associated nephrotoxicity in the critically ill: a retrospective multivariate regression analysis*. Crit Care Med 2014; 42:2527.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vuagnat A, Stern R, Lotthe A, et al. High dose vancomycin for osteomyelitis: continuous vs. intermittent infusion. J Clin Pharm Ther 2004; 29:351.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ingram PR, Lye DC, Fisher DA, et al. Nephrotoxicity of continuous versus intermittent infusion of vancomycin in outpatient parenteral antimicrobial therapy. Int J Antimicrob Agents 2009; 34:570.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Verrall AJ, Llorin R, Tam VH, et al. Efficacy of continuous infusion of vancomycin for the outpatient treatment of methicillin-resistant Staphylococcus aureus infections. J Antimicrob Chemother 2012; 67:2970.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Steinmetz T, Eliakim-Raz N, Goldberg E, et al. Association of vancomycin serum concentrations with efficacy in patients with MRSA infections: a systematic review and meta-analysis. Clin Microbiol Infect 2015; 21:665.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prybylski JP. Vancomycin Trough Concentration as a Predictor of Clinical Outcomes in Patients with Staphylococcus aureus Bacteremia: A Meta-analysis of Observational Studies. Pharmacotherapy 2015; 35:889.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu J, Tong SYC, Davis JS, et al. Vancomycin Exposure and Acute Kidney Injury Outcome: A Snapshot From the CAMERA2 Study. Open Forum Infect Dis 2020; 7:ofaa538.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patel N, Pai MP, Rodvold KA, et al. Vancomycin: we can't get there from here. Clin Infect Dis 2011; 52:969.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pai MP, Neely M, Rodvold KA, Lodise TP. Innovative approaches to optimizing the delivery of vancomycin in individual patients. Adv Drug Deliv Rev 2014; 77:50.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haeseker M, Croes S, Neef C, et al. Evaluation of Vancomycin Prediction Methods Based on Estimated Creatinine Clearance or Trough Levels. Ther Drug Monit 2016; 38:120.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Neely MN, Youn G, Jones B, et al. Are vancomycin trough concentrations adequate for optimal dosing? Antimicrob Agents Chemother 2014; 58:309.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holmes NE, Turnidge JD, Munckhof WJ, et al. Vancomycin AUC/MIC ratio and 30-day mortality in patients with Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2013; 57:1654.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lewis P. Vancomycin Area Under the Curve Simplified. Ther Drug Monit 2018; 40:377.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Finch NA, Zasowski EJ, Murray KP, et al. A Quasi-Experiment To Study the Impact of Vancomycin Area under the Concentration-Time Curve-Guided Dosing on Vancomycin-Associated Nephrotoxicity. Antimicrob Agents Chemother 2017; 61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reardon J, Lau TT, Ensom MH. Vancomycin loading doses: a systematic review. Ann Pharmacother 2015; 49:557.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosini JM, Laughner J, Levine BJ, et al. A randomized trial of loading vancomycin in the emergency department. Ann Pharmacother 2015; 49:6.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosini JM, Davis JJ, Muenzer J, et al. High Single-dose Vancomycin Loading Is Not Associated With Increased Nephrotoxicity in Emergency Department Sepsis Patients. Acad Emerg Med 2016; 23:744.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Truong J, Levkovich BJ, Padiglione AA. Simple approach to improving vancomycin dosing in intensive care: a standardised loading dose results in earlier therapeutic levels. Intern Med J 2012; 42:23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fuchs A, Csajka C, Thoma Y, et al. Benchmarking therapeutic drug monitoring software: a review of available computer tools. Clin Pharmacokinet 2013; 52:9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heil EL, Claeys KC, Mynatt RP, et al. Making the change to area under the curve-based vancomycin dosing. Am J Health Syst Pharm 2018; 75:1986.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gregory ER, Burgess DR, Cotner SE, et al. Vancomycin Area Under the Curve Dosing and Monitoring at an Academic Medical Center: Transition Strategies and Lessons Learned. J Pharm Pract 2020; 33:774.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Turner RB, Kojiro K, Shephard EA, et al. Review and Validation of Bayesian Dose-Optimizing Software and Equations for Calculation of the Vancomycin Area Under the Curve in Critically Ill Patients. Pharmacotherapy 2018; 38:1174.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Olney KB, Wallace KL, Mynatt RP, et al. Comparison of Bayesian-derived and first-order analytic equations for calculation of vancomycin area under the curve. Pharmacotherapy 2022; 42:284.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lodise TP, Drusano GL, Zasowski E, et al. Vancomycin exposure in patients with methicillin-resistant Staphylococcus aureus bloodstream infections: how much is enough? Clin Infect Dis 2014; 59:666.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Begg EJ, Barclay ML, Duffull SB. A suggested approach to once-daily aminoglycoside dosing. Br J Clin Pharmacol 1995; 39:605.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis 2006; 42 Suppl 1:S35.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marsot A, Boulamery A, Bruguerolle B, Simon N. Vancomycin: a review of population pharmacokinetic analyses. Clin Pharmacokinet 2012; 51:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nix DE, Davis LE, Matthias KR. The relationship of vancomycin 24-hour AUC and trough concentration. Am J Health Syst Pharm 2022; 79:534.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Howden BP, Ward PB, Charles PG, et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 2004; 38:521.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moellering RC Jr. Monitoring serum vancomycin levels: climbing the mountain because it is there? Clin Infect Dis 1994; 18:544.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DiMondi VP, Rafferty K. Review of continuous-infusion vancomycin. Ann Pharmacother 2013; 47:219.
          </a>
         </li>
         <li class="breakAll">
          United States Centers for Disease Control and Prevention. Defining adult overweight and obesity. https://www.cdc.gov/obesity/adult/defining.html (Accessed on April 01, 2019).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bowers RD, Cooper AA, Wente CL, et al. Evaluation of a vancomycin dosing nomogram in obese patients weighing at least 100 kilograms. Pharm Pract (Granada) 2018; 16:1204.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crass RL, Dunn R, Hong J, et al. Dosing vancomycin in the super obese: less is more. J Antimicrob Chemother 2018; 73:3081.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rybak MJ, Lomaestro BM, Rotschafer JC, et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 2009; 49:325.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brown M, Polisetty R, Gracely EJ, et al. Weight-based loading of vancomycin in patients on hemodialysis. Clin Infect Dis 2011; 53:164.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vandecasteele SJ, De Bacquer D, De Vriese AS. Implementation of a dose calculator for vancomycin to achieve target trough levels of 15-20 microg/mL in persons undergoing hemodialysis. Clin Infect Dis 2011; 53:124.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Decker BS, Kays MB, Chambers M, et al. Vancomycin pharmacokinetics and pharmacodynamics during short daily hemodialysis. Clin J Am Soc Nephrol 2010; 5:1981.
          </a>
         </li>
         <li class="breakAll">
          Lewis SJ, Mueller BA. Contemporary Vancomycin Dosing in Chronic Hemodialysis (HD) Patients Does Not Meet AUC Targets: Development of a New Dosing Model Using Monte Carlo Simulation (MCS). College of Pharmacy: University of Michigan. 1984.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lucksiri A, Scott MK, Mueller BA, et al. CAHP-210 dialyzer influence on intra-dialytic vancomycin removal. Nephrol Dial Transplant 2002; 17:1649.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nyman HA, Agarwal A, Senekjian HO, et al. Removal of vancomycin administered during dialysis by a high-flux dialyzer. Hemodial Int 2018; 22:383.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cimino C, Burnett Y, Vyas N, Norris AH. Post-Dialysis Parenteral Antimicrobial Therapy in Patients Receiving Intermittent High-Flux Hemodialysis. Drugs 2021; 81:555.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pai AB, Pai MP. Vancomycin dosing in high flux hemodialysis: a limited-sampling algorithm. Am J Health Syst Pharm 2004; 61:1812.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crew P, Heintz SJ, Heintz BH. Vancomycin dosing and monitoring for patients with end-stage renal disease receiving intermittent hemodialysis. Am J Health Syst Pharm 2015; 72:1856.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chaijamorn W, Jitsurong A, Wiwattanawongsa K, et al. Vancomycin clearance during continuous venovenous haemofiltration in critically ill patients. Int J Antimicrob Agents 2011; 38:152.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sin JH, Newman K, Elshaboury RH, et al. Prospective evaluation of a continuous infusion vancomycin dosing nomogram in critically ill patients undergoing continuous venovenous haemofiltration. J Antimicrob Chemother 2018; 73:199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Covajes C, Scolletta S, Penaccini L, et al. Continuous infusion of vancomycin in septic patients receiving continuous renal replacement therapy. Int J Antimicrob Agents 2013; 41:261.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pongchaidecha M, Changpradub D, Bannalung K, et al. Vancomycin Area under the Curve and Pharmacokinetic Parameters during the First 24 Hours of Treatment in Critically Ill Patients using Bayesian Forecasting. Infect Chemother 2020; 52:573.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Drouet M, Chai F, Barthélémy C, et al. Influence of vancomycin infusion methods on endothelial cell toxicity. Antimicrob Agents Chemother 2015; 59:930.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alvarez-Arango S, Ogunwole SM, Sequist TD, et al. Vancomycin Infusion Reaction - Moving beyond "Red Man Syndrome". N Engl J Med 2021; 384:1283.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sivagnanam S, Deleu D. Red man syndrome. Crit Care 2003; 7:119.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Polk RE, Israel D, Wang J, et al. Vancomycin skin tests and prediction of "red man syndrome" in healthy volunteers. Antimicrob Agents Chemother 1993; 37:2139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lodise TP, Lomaestro B, Graves J, Drusano GL. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother 2008; 52:1330.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carreno JJ, Kenney RM, Lomaestro B. Vancomycin-associated renal dysfunction: where are we now? Pharmacotherapy 2014; 34:1259.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roy AK, Mc Gorrian C, Treacy C, et al. A Comparison of Traditional and Novel Definitions (RIFLE, AKIN, and KDIGO) of Acute Kidney Injury for the Prediction of Outcomes in Acute Decompensated Heart Failure. Cardiorenal Med 2013; 3:26.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Hal SJ, Paterson DL, Lodise TP. Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter. Antimicrob Agents Chemother 2013; 57:734.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Appel GB, Given DB, Levine LR, Cooper GL. Vancomycin and the kidney. Am J Kidney Dis 1986; 8:75.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bailie GR, Neal D. Vancomycin ototoxicity and nephrotoxicity. A review. Med Toxicol Adverse Drug Exp 1988; 3:376.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Downs NJ, Neihart RE, Dolezal JM, Hodges GR. Mild nephrotoxicity associated with vancomycin use. Arch Intern Med 1989; 149:1777.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rybak MJ, Albrecht LM, Boike SC, Chandrasekar PH. Nephrotoxicity of vancomycin, alone and with an aminoglycoside. J Antimicrob Chemother 1990; 25:679.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sinha Ray A, Haikal A, Hammoud KA, Yu AS. Vancomycin and the Risk of AKI: A Systematic Review and Meta-Analysis. Clin J Am Soc Nephrol 2016; 11:2132.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lodise TP, Patel N, Lomaestro BM, et al. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis 2009; 49:507.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suzuki Y, Kawasaki K, Sato Y, et al. Is peak concentration needed in therapeutic drug monitoring of vancomycin? A pharmacokinetic-pharmacodynamic analysis in patients with methicillin-resistant staphylococcus aureus pneumonia. Chemotherapy 2012; 58:308.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jeffres MN, Isakow W, Doherty JA, et al. A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia. Clin Ther 2007; 29:1107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Legg A, Meagher N, Johnson SA, et al. Risk Factors for Nephrotoxicity in Methicillin-Resistant Staphylococcus aureus Bacteraemia: A Post Hoc Analysis of the CAMERA2 Trial. Clin Drug Investig 2023; 43:23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tong SYC, Lye DC, Yahav D, et al. Effect of Vancomycin or Daptomycin With vs Without an Antistaphylococcal β-Lactam on Mortality, Bacteremia, Relapse, or Treatment Failure in Patients With MRSA Bacteremia: A Randomized Clinical Trial. JAMA 2020; 323:527.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Legg A, Roberts MA, Davies J, et al. Longer-term Mortality and Kidney Outcomes of Participants in the Combination Antibiotics for Methicillin-Resistant Staphylococcus aureus (CAMERA2) Trial: A Post Hoc Analysis. Open Forum Infect Dis 2023; 10:ofad337.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alosaimy S, Rybak MJ, Sakoulas G. Understanding vancomycin nephrotoxicity augmented by β-lactams: a synthesis of endosymbiosis, proximal renal tubule mitochondrial metabolism, and β-lactam chemistry. Lancet Infect Dis 2023.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rybak MJ, Abate BJ, Kang SL, et al. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob Agents Chemother 1999; 43:1549.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Avedissian SN, Pais GM, Liu J, et al. Piperacillin-Tazobactam Added to Vancomycin Increases Risk for Acute Kidney Injury: Fact or Fiction? Clin Infect Dis 2020; 71:426.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Navalkele B, Pogue JM, Karino S, et al. Risk of Acute Kidney Injury in Patients on Concomitant Vancomycin and Piperacillin-Tazobactam Compared to Those on Vancomycin and Cefepime. Clin Infect Dis 2017; 64:116.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rutter WC, Cox JN, Martin CA, et al. Nephrotoxicity during Vancomycin Therapy in Combination with Piperacillin-Tazobactam or Cefepime. Antimicrob Agents Chemother 2017; 61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Downes KJ, Cowden C, Laskin BL, et al. Association of Acute Kidney Injury With Concomitant Vancomycin and Piperacillin/Tazobactam Treatment Among Hospitalized Children. JAMA Pediatr 2017; 171:e173219.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robertson AD, Li C, Hammond DA, Dickey TA. Incidence of Acute Kidney Injury Among Patients Receiving the Combination of Vancomycin with Piperacillin-Tazobactam or Meropenem. Pharmacotherapy 2018; 38:1184.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trinh TD, Zasowski EJ, Lagnf AM, et al. Combination Vancomycin/Cefazolin (VAN/CFZ) for Methicillin-Resistant Staphylococcus aureus (MRSA) Bloodstream Infections (BSI). Open Forum Infect Dis 2017; 4:S281.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zasowski EJ, Trinh TD, Atwan SM, et al. The Impact of Concomitant Empiric Cefepime on Patient Outcomes of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections Treated With Vancomycin. Open Forum Infect Dis 2019; 6:ofz077.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dilworth TJ, Ibrahim O, Hall P, et al. β-Lactams enhance vancomycin activity against methicillin-resistant Staphylococcus aureus bacteremia compared to vancomycin alone. Antimicrob Agents Chemother 2014; 58:102.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alosaimy S, Sabagha NL, Lagnf AM, et al. Monotherapy with Vancomycin or Daptomycin versus Combination Therapy with β-Lactams in the Treatment of Methicillin-Resistant Staphylococcus Aureus Bloodstream Infections: A Retrospective Cohort Analysis. Infect Dis Ther 2020; 9:325.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Qian ET, Casey JD, Wright A, et al. Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acute Infection: The ACORN Randomized Clinical Trial. JAMA 2023; 330:1557.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tong SYC, Venkatesh B, McCreary EK. Acute Kidney Injury With Empirical Antibiotics for Sepsis. JAMA 2023; 330:1531.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miano TA, Hennessy S, Yang W, et al. Association of vancomycin plus piperacillin-tazobactam with early changes in creatinine versus cystatin C in critically ill adults: a prospective cohort study. Intensive Care Med 2022; 48:1144.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Filippone EJ, Kraft WK, Farber JL. The Nephrotoxicity of Vancomycin. Clin Pharmacol Ther 2017; 102:459.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klibanov OM, Filicko JE, DeSimone JA Jr, Tice DS. Sensorineural hearing loss associated with intrathecal vancomycin. Ann Pharmacother 2003; 37:61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Forouzesh A, Moise PA, Sakoulas G. Vancomycin ototoxicity: a reevaluation in an era of increasing doses. Antimicrob Agents Chemother 2009; 53:483.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brummett RE. Ototoxicity of vancomycin and analogues. Otolaryngol Clin North Am 1993; 26:821.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brummett RE, Fox KE, Jacobs F, et al. Augmented gentamicin ototoxicity induced by vancomycin in guinea pigs. Arch Otolaryngol Head Neck Surg 1990; 116:61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Hoog M, van Zanten BA, Hop WC, et al. Newborn hearing screening: tobramycin and vancomycin are not risk factors for hearing loss. J Pediatr 2003; 142:41.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 484 Version 58.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32191793" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6732213" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Pharmacokinetics of vancomycin in patients with various degrees of renal function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6101256" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Vancomycin therapy in patients with impaired renal function: a nomogram for dosage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4080569" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : A simplified dosing method for initiating vancomycin therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2044330" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : An updated comparison of drug dosing methods. Part IV: Vancomycin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33740042" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Vancomycin Area Under the Curve-Guided Dosing and Monitoring for Adult and Pediatric Patients With Suspected or Documented Serious Methicillin-Resistant Staphylococcus aureus Infections: Putting the Safety of Our Patients First.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33740050" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Should Therapeutic Drug Monitoring Based on the Vancomycin Area Under the Concentration-Time Curve Be Standard for Serious Methicillin-Resistant Staphylococcus aureus Infections?-No.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32898221" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Vancomycin Advanced Therapeutic Drug Monitoring: Exercise in Futility or Virtuous Endeavor to Improve Drug Efficacy and Safety?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31157362" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : 60 Plus Years Later and We Are Still Trying to Learn How to Dose Vancomycin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31157362" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : 60 Plus Years Later and We Are Still Trying to Learn How to Dose Vancomycin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3415206" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Vancomycin pharmacokinetics in patients with various degrees of renal function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16569854" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Impaired target site penetration of vancomycin in diabetic patients following cardiac surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8961057" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Penetration of vancomycin into human lung tissue.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25627406" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : A Larger Dose of Vancomycin Is Required in Adult Neurosurgical Intensive Care Unit Patients Due to Augmented Clearance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15509186" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26555059" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Impact of area under the concentration-time curve to minimum inhibitory concentration ratio on vancomycin treatment outcomes in methicillin-resistant Staphylococcus aureus bacteraemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21460309" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29203493" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Prospective Trial on the Use of Trough Concentration versus Area under the Curve To Determine Therapeutic Vancomycin Dosing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29084753" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Identification of Vancomycin Exposure-Toxicity Thresholds in Hospitalized Patients Receiving Intravenous Vancomycin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31157370" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : The Emperor's New Clothes: PRospective Observational Evaluation of the Association Between Initial VancomycIn Exposure and Failure Rates Among ADult HospitalizEd Patients With Methicillin-resistant Staphylococcus aureus Bloodstream Infections (PROVIDE).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25753631" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Association between vancomycin day 1 exposure profile and outcomes among patients with methicillin-resistant Staphylococcus aureus infective endocarditis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17035423" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17452488" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15184410" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17060545" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18591266" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17516395" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Point: Vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant Staphylococcus aureus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11502515" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Continuous versus intermittent infusion of vancomycin in severe Staphylococcal infections: prospective multicenter randomized study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22878490" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Serum vancomycin levels resulting from continuous or intermittent infusion in critically ill burn patients with or without continuous renal replacement therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22459156" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Continuous intravenous administration of vancomycin in medical intensive care unit patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25083977" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Vancomycin-associated nephrotoxicity in the critically ill: a retrospective multivariate regression analysis*.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15271102" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : High dose vancomycin for osteomyelitis: continuous vs. intermittent infusion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19744837" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Nephrotoxicity of continuous versus intermittent infusion of vancomycin in outpatient parenteral antimicrobial therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22915464" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Efficacy of continuous infusion of vancomycin for the outpatient treatment of methicillin-resistant Staphylococcus aureus infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25887712" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Association of vancomycin serum concentrations with efficacy in patients with MRSA infections: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26497475" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Vancomycin Trough Concentration as a Predictor of Clinical Outcomes in Patients with Staphylococcus aureus Bacteremia: A Meta-analysis of Observational Studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33335938" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Vancomycin Exposure and Acute Kidney Injury Outcome: A Snapshot From the CAMERA2 Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21460308" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Vancomycin: we can't get there from here.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24910345" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Innovative approaches to optimizing the delivery of vancomycin in individual patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26418699" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Evaluation of Vancomycin Prediction Methods Based on Estimated Creatinine Clearance or Trough Levels.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24165176" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Are vancomycin trough concentrations adequate for optimal dosing?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23335735" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Vancomycin AUC/MIC ratio and 30-day mortality in patients with Staphylococcus aureus bacteremia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29494420" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Vancomycin Area Under the Curve Simplified.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28923869" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : A Quasi-Experiment To Study the Impact of Vancomycin Area under the Concentration-Time Curve-Guided Dosing on Vancomycin-Associated Nephrotoxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25712445" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Vancomycin loading doses: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25358330" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : A randomized trial of loading vancomycin in the emergency department.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26850378" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : High Single-dose Vancomycin Loading Is Not Associated With Increased Nephrotoxicity in Emergency Department Sepsis Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22276559" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Simple approach to improving vancomycin dosing in intensive care: a standardised loading dose results in earlier therapeutic levels.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23196713" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Benchmarking therapeutic drug monitoring software: a review of available computer tools.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30333114" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Making the change to area under the curve-based vancomycin dosing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30852937" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Vancomycin Area Under the Curve Dosing and Monitoring at an Academic Medical Center: Transition Strategies and Lessons Learned.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30362592" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Review and Validation of Bayesian Dose-Optimizing Software and Equations for Calculation of the Vancomycin Area Under the Curve in Critically Ill Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35134264" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Comparison of Bayesian-derived and first-order analytic equations for calculation of vancomycin area under the curve.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24867791" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Vancomycin exposure in patients with methicillin-resistant Staphylococcus aureus bloodstream infections: how much is enough?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7654477" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : A suggested approach to once-daily aminoglycoside dosing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16323118" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : The pharmacokinetic and pharmacodynamic properties of vancomycin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22149255" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Vancomycin: a review of population pharmacokinetic analyses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34849533" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : The relationship of vancomycin 24-hour AUC and trough concentration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21208910" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14765345" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8038307" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Monitoring serum vancomycin levels: climbing the mountain because it is there?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23386074" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Review of continuous-infusion vancomycin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23386074" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Review of continuous-infusion vancomycin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30416622" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Evaluation of a vancomycin dosing nomogram in obese patients weighing at least 100 kilograms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30203073" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Dosing vancomycin in the super obese: less is more.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19569969" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21690623" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Weight-based loading of vancomycin in patients on hemodialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21690618" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Implementation of a dose calculator for vancomycin to achieve target trough levels of 15-20 microg/mL in persons undergoing hemodialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20616157" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Vancomycin pharmacokinetics and pharmacodynamics during short daily hemodialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20616157" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Vancomycin pharmacokinetics and pharmacodynamics during short daily hemodialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12198218" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : CAHP-210 dialyzer influence on intra-dialytic vancomycin removal.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29380499" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Removal of vancomycin administered during dialysis by a high-flux dialyzer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33591549" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Post-Dialysis Parenteral Antimicrobial Therapy in Patients Receiving Intermittent High-Flux Hemodialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15462252" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Vancomycin dosing in high flux hemodialysis: a limited-sampling algorithm.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26490819" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Vancomycin dosing and monitoring for patients with end-stage renal disease receiving intermittent hemodialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21636256" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Vancomycin clearance during continuous venovenous haemofiltration in critically ill patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29040561" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Prospective evaluation of a continuous infusion vancomycin dosing nomogram in critically ill patients undergoing continuous venovenous haemofiltration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23312601" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Continuous infusion of vancomycin in septic patients receiving continuous renal replacement therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33263245" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Vancomycin Area under the Curve and Pharmacokinetic Parameters during the First 24 Hours of Treatment in Critically Ill Patients using Bayesian Forecasting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25421476" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Influence of vancomycin infusion methods on endothelial cell toxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33830710" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Vancomycin Infusion Reaction - Moving beyond "Red Man Syndrome".
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12720556" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Red man syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8257136" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Vancomycin skin tests and prediction of "red man syndrome" in healthy volunteers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18227177" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25220436" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Vancomycin-associated renal dysfunction: where are we now?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23801998" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : A Comparison of Traditional and Novel Definitions (RIFLE, AKIN, and KDIGO) of Acute Kidney Injury for the Prediction of Outcomes in Acute Decompensated Heart Failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23165462" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3526874" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Vancomycin and the kidney.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3057327" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Vancomycin ototoxicity and nephrotoxicity. A review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2764651" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Mild nephrotoxicity associated with vancomycin use.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2351627" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Nephrotoxicity of vancomycin, alone and with an aminoglycoside.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27895134" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Vancomycin and the Risk of AKI: A Systematic Review and Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19586413" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23147106" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Is peak concentration needed in therapeutic drug monitoring of vancomycin? A pharmacokinetic-pharmacodynamic analysis in patients with methicillin-resistant staphylococcus aureus pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17692725" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36217068" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Risk Factors for Nephrotoxicity in Methicillin-Resistant Staphylococcus aureus Bacteraemia: A Post Hoc Analysis of the CAMERA2 Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32044943" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Effect of Vancomycin or Daptomycin With vs Without an Antistaphylococcalβ-Lactam on Mortality, Bacteremia, Relapse, or Treatment Failure in Patients With MRSA Bacteremia: A Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37496601" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Longer-term Mortality and Kidney Outcomes of Participants in the Combination Antibiotics for Methicillin-Resistant Staphylococcus aureus (CAMERA2) Trial: A Post Hoc Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37883984" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Understanding vancomycin nephrotoxicity augmented byβ-lactams: a synthesis of endosymbiosis, proximal renal tubule mitochondrial metabolism, andβ-lactam chemistry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10390201" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31833540" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Piperacillin-Tazobactam Added to Vancomycin Increases Risk for Acute Kidney Injury: Fact or Fiction?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27986669" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Risk of Acute Kidney Injury in Patients on Concomitant Vancomycin and Piperacillin-Tazobactam Compared to Those on Vancomycin and Cefepime.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27895019" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Nephrotoxicity during Vancomycin Therapy in Combination with Piperacillin-Tazobactam or Cefepime.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28973124" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Association of Acute Kidney Injury With Concomitant Vancomycin and Piperacillin/Tazobactam Treatment Among Hospitalized Children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30175410" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Incidence of Acute Kidney Injury Among Patients Receiving the Combination of Vancomycin with Piperacillin-Tazobactam or Meropenem.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Combination Vancomycin/Cefazolin (VAN/CFZ) for Methicillin-Resistant Staphylococcus aureus (MRSA) Bloodstream Infections (BSI)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31338381" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : The Impact of Concomitant Empiric Cefepime on Patient Outcomes of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections Treated With Vancomycin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24145519" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : β-Lactams enhance vancomycin activity against methicillin-resistant Staphylococcus aureus bacteremia compared to vancomycin alone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32248513" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Monotherapy with Vancomycin or Daptomycin versus Combination Therapy withβ-Lactams in the Treatment of Methicillin-Resistant Staphylococcus Aureus Bloodstream Infections: A Retrospective Cohort Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37837651" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acute Infection: The ACORN Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37837650" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Acute Kidney Injury With Empirical Antibiotics for Sepsis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35833959" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Association of vancomycin plus piperacillin-tazobactam with early changes in creatinine versus cystatin C in critically ill adults: a prospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28474732" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : The Nephrotoxicity of Vancomycin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12503934" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Sensorineural hearing loss associated with intrathecal vancomycin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19001107" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Vancomycin ototoxicity: a reevaluation in an era of increasing doses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8233491" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Ototoxicity of vancomycin and analogues.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2294943" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Augmented gentamicin ototoxicity induced by vancomycin in guinea pigs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12520253" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Newborn hearing screening: tobramycin and vancomycin are not risk factors for hearing loss.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
